The S&P 500 ended marginally lower on Thursday after a report that an experimental antiviral drug for the coronavirus flopped in its first randomized clinical trial, denting earlier optimism that the impact of the pandemic on the labor market was nearing an end.
U.S. coronavirus deaths topped 49,000 on Thursday as the number of lives lost in April rises by an average of 2,000 a day, according to a Reuters tally.
Zoom is more popular than ever, but it’s also been criticized for poor security and privacy. Here’s how to still use it and stay safe. …read more […]
New York Governor Andrew Cuomo said on Thursday a preliminary survey found that nearly 14% tested positive for antibodies against the novel coronavirus, suggesting that as many as 2.7 million New Yorkers may have been infected with the disease.
An array of businesses prepared on Thursday to reopen in Georgia and a handful of other U.S. states for the first time in a month, as another week of massive unemployment claims highlighted the grim economic toll of the coronavirus pandemic.
A Tyson Foods Inc unit said on Thursday it will temporarily halt production at a beef facility in Pasco, Washington, adding to the meat processing plant the company has had to shutter as it tests workers for COVID-19.
Oil soared on Thursday, extending its rebound after major oil-producing nations said they would accelerate planned production cuts to combat the dramatic slump in demand due to the COVID-19 pandemic.
Toyota Motor Corp said on Thursday it expects to gradually resume North American production starting May 4 and will impose significant new safety procedures after it halted operations in March because of the coronavirus pandemic.
According to a report by the Financial Times, Gilead Science Inc’s experimental antiviral drug Remdesiver, which was being used to treat coronavirus, failed to improve the health of patients. Yahoo Finance’s Anjalee Khemlani joins The Final Round panel to break down the latest news about the coronavirus. …read more […]
(Bloomberg) — Gilead Sciences Inc. analysts offered a broad range of views on the inadvertently leaked abstract that indicated the company’s remdesivir failed to provide a benefit in a placebo-controlled trial in Chinese patients with severe Covid-19.Skeptical analysts included Baird’s Brian Skorney, who said the negative results “should be very sobering” given the lack of an improvement and argued that the result is “pretty close to a worst case scenario.” Others on Wall Street argued that investors should hold off on jumping to conclusions.“The bottom line is that stating the trial flopped appears overly aggressive and premature, particularly in light …read more […]
Argentina plans to issue a decree setting a higher local oil barrel price to protect the domestic industry from being further decimated by a collapse in global prices and slumping fuel demand due to the coronavirus pandemic, two industry sources told Reuters on Thursday.
The U.S. House of Representatives returned to Washington on Thursday to pass a $484 billion coronavirus relief bill, funding small businesses and hospitals and pushing the total spending response to the crisis to an unprecedented nearly $3 trillion.
How far are we from a viable COVID-19 treatment? Worldwide, over 178,000 people have died so far, with confirmed cases numbering more than 2,500,000. More than 150 drugs are being researched as possible treatments, by companies big and small.Pluristem Therapeutics (PSTI) falls squarely into the latter category. The micro-cap pharma company has been grabbing some attention with its potential COVID-19 treatment.Following a virtual fireside chat with Pluristem’s President and CEO Yaky Yanay, H.C. Wainwright’s Swayampakula Ramakanth noted, “In our view, with the ongoing pandemic affecting nearly every country and stressing healthcare systems around the world, there is an urgent need …read more […]
The coronavirus pandemic showed signs of waning on Thursday, but its economic impact was as destructive as ever. …read more […]
Facebook Inc has removed “pseudoscience” as an option for advertisers who want to target audiences, a category available until this week even as the world’s largest social media network vowed to curb misinformation about the COVID-19 pandemic.
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.
